Advancing Inclusive Clinical Research for Rare Diseases

In Conversation with Pamela Fearon

In this engaging interview, Ariel Katz, CEO and Co-founder at H1, sat down with Pam Fearon, Vice President of Global Study Operations at BioMarin, to discuss how the company is advancing inclusive clinical research for rare diseases. Despite the inherent challenge of having much smaller patient populations in this therapeutic area, BioMarin leverages innovative approaches to increase diversity and inclusive patient participation. The company utilizes technology like the H1 platform to more efficiently identify viable trial sites with diverse demographics. BioMarin is also reducing participation barriers through telemedicine and multilingual materials. With these forward-thinking strategies, BioMarin is paving the way as an industry leader in ensuring clinical trials for rare diseases have representative, equitable enrollment.

Listen to the full interview to hear best practices from Pam on how BioMarin is decreasing operational timelines, leveraging AI and technology, adhering to evolving FDA guidelines, and partnering with sites – all while prioritizing diversity in their rare disease studies.

"Because of the advances in technology platforms, H1 being one of them, we are able to decrease the time it takes for the initial vetting of our sites, and this has proven to be an efficiency gain for us in the clinical operations world."

The interview covers:

• Site and PI selection for rare and ultra-rare clinical trials
• How to decrease time in vetting sites to increase efficiency by using known criteria
• Maintaining aggressive timelines with technology and generative AI
• FDA guidelines and helping underserved communities by designing more inclusive clinical trials

Watch the interview:

 

Interested in seeing how H1 can support your clinical trials to be more inclusive? Request a demo to learn more.